Business Wire

IDEMIA

4.6.2021 16:16:11 CEST | Business Wire | Press release

Share
IDEMIA Collaborates With ClimateSeed to Invest in a Carbon Project in India to Offer Truly Sustainable Payment Cards

For decades, the “take-make-waste” model has ruled the global economy. However, we are now seeing a paradigm shift in Banks’ and fin techs’ strategic values; they are seeking a “reduce-recycle-offset” model to reduce their carbon footprint and preserve the planet. There is also an strong appetite in the market for greener solutions, as customers are becoming more deeply committed to the protection of the environment.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210604005402/en/

With GREENPAY, IDEMIA is taking an end-to-end sustainability approach to the entire payment card lifecycle - from chip module to card body, to digital customer onboarding, to card personalization & fulfillment, to transport, to recycling once expired. GREENPAY aims to minimize the carbon footprint of payment cards by reducing and recycling at every step of this life cycle. These efforts are dramatically decreasing the footprint and for the residual footprint, IDEMIA has collaborated with ClimateSeed, a leading social initiatives launched by BNP Paribas in collaboration with Nobel Peace Prize Laureate Prof. Yunus’ team.

ClimateSeed will help IDEMIA in offsetting and compensating the residual footprint with investment in various sustainability projects. These projects are not only doing the environment good, but also contributing to several of the other 16 United Nations’ sustainable development goals.

IDEMIA is proud to share that the first project in which we have chosen to invest thanks to our ClimateSeed partnership, is the India-based “Khasi Hills community Carbon project”, employing 5,000-plus people, conserving existing and regenerating degraded forests in Meghalaya, north-eastern India. The young, regenerating forests are absorbing carbon at an annual rate of 1.75 tC/ha.

Amanda Gourbault , IDEMIA Executive VP Financial Institutions, said: “We are proud to be living up to our climate change pledges. We believe we should take real-life steps to help preserve the environment. Thanks to our ClimateSeed partnership, we are doing our bit to achieving a zero carbon economy and to champion sustainable development.”

Arnaud Despontin , IDEMIA VP Corporate Social Responsibility, said: “This project is a major step towards the achievement of our CSR goals to uphold and step up our support for local communities - specifically the underprivileged - while advocating more effective environmental conservation. IDEMIA staff selected the following four key priorities in a company-wide survey: Climate action, no poverty, clean water,sanitation and quality education. This venture furthers three out of the four goals, namely climate action, quality education and reducing poverty.”

Amit Kakatikar , Regional Director- Financial Institutions, India, said: ‘From reducing the carbon footprint of the card to implementing eco-designed packaging, and replacing paper with digital services, everyone in the payment ecosystem has a part to play to ensure that we deliver to our consumers a payment tool with the lowest possible carbon footprint. There is only one planet Earth, we all have a responsibility to protect it. Our Banking and Fintech partners in India are excited to adopt Green payment initiatives. Their enthusiasm is further augmented by IDEMIA’s investment in a project that builds a better India.”

About IDEMIA

IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space.

Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors. With close to 15,000 employees around the world, IDEMIA serves clients in 180 countries.

For further details, go to www.idemia.com / and follow us @IDEMIAGroup on Twitter

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye